by Marcia Nusgart, Executive Director, Alliance of Wound Care Stakeholders
Editor's note:This blog post is part of the WoundSource Trending Topics series, bringing you insight into the latest...
Gaithersburg, MD – November 7, 2016 – The new Nexodyn® AOS Wound Care Solution, cleared for sale by the FDA, is now starting to be available in the USA, promoted and commercialized by a leading Italian pharmaceutical company Angelini, as a result of an exclusive partnership with the Swiss Company APR Applied Pharma Research (APR), the owner and developer of the proprietary, patented technology TEHCLO®, for the production of acidic super-oxidizing solutions.
Nexodyn® is formulated to help cleanse and moisten the wound environment by removing dirt, debris and foreign material by flushing across the wound. Nexodyn® is intended for use, under the supervision of healthcare professionals, to treat acute and chronic dermal lesions (such as leg ulcers, post-surgical wounds or 1st and 2nd degree burns) and minor cuts, burns, skin irritations and superficial abrasions.
"With this latest product launch, Angelini aims to strengthen its position in the wound care market in the United States and worldwide. We look to provide healthcare professionals and patients with a range of wound treatment options based on innovative technologies, like TEHCLO® by APR, that offer important benefits to users", states Todd Maddock, Angelini US CEO.
Nexodyn®, characterized by an acidic pH between 2.5 and 3.0, has excellent cell viability preservation features, so as not to negatively interfere with the natural physiological healing process and epthelialization. Its antimicrobial preservative effectiveness has been demonstrated by in vitro testing against P. aeruginosa, E. coli, S. aureus, S. epidermidis, S. pyogenes, E. gergoviae, C. albicans and A. niger.
"After a first, successful launch last year in Italy, we are proud to strengthen our partnership with a leading company such as Angelini in the challenging and dynamic USA market", said Paolo Galfetti, Chief Executive Officer of APR. "Renewing its trust in APR, our partner Angelini has demonstrated its belief in the great opportunities provided by the value-added solutions we bring to the market. As an independent developer of science-driven healthcare products, we develop solutions specifically designed to address unmet medical needs for license to healthcare companies for their commercialization."
About APR Applied Pharma Research s.a.
APR is a Swiss, independent developer of science driven, patent protected healthcare products. The Company identifies, develops and licenses science driven, value added products designed to address patient or consumer needs in niche or rare therapeutic areas on a global basis. In particular, APR's business model is currently focused on 2 (two) pillars: (i) internally developed and financed (alone or together with our co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets combined with a compelling pipeline of products at different stage of development. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries with international sales on a worldwide basis.
Angelini is a privately-held, mid-sized international manufacturer and marketer of pharmaceutical and healthcare products in the pharmaceutical and mass-market sectors. Founded in Italy in 1919, the group has operations in 20 countries and employs 5,000 people. Angelini Pharma Inc. is the American business unit of Angelini, providing innovative solutions to promote infection control, antisepsis, disinfection, and wound healing to our targeted customers.
The views and opinions expressed in this blog are solely those of the author, and do not represent the views of WoundSource, Kestrel Health Information, Inc., its affiliates, or subsidiary companies.